Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02357992|
Recruitment Status : Active, not recruiting
First Posted : February 6, 2015
Last Update Posted : May 15, 2019
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC.
Specifically, researchers want to learn if standard SRT has as good of an outcome at 3 years after the procedure. The safety of the study treatment will also be analyzed.
|Condition or disease||Intervention/treatment||Phase|
|Lung Cancer||Radiation: Stereotactic Body Radiotherapy (SABR)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||122 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy|
|Actual Study Start Date :||April 5, 2010|
|Estimated Primary Completion Date :||April 2025|
|Estimated Study Completion Date :||April 2025|
Experimental: Stereotactic Radiotherapy (SRT)
Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.
50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor.
Radiation: Stereotactic Body Radiotherapy (SABR)
SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
- Overall Survival (OS) for Stage I Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy (SABR) [ Time Frame: 3 years ]OS defined as the length of time measured from the start of treatment until death. Kaplan-Meier method used to estimate OS.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02357992
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Jack Roth, MD, BA||M.D. Anderson Cancer Center|